Jazz Pharmaceuticals price target lowered to $254 from $256 at Truist
Truist analyst Gregory Renza lowered the firm's price target on Jazz Pharmaceuticals to $254 from $256 and keeps a Buy rating on the shares as part of a broader research note updating the firm's models and previewing Q2 earnings in Biotech. The firm is anticipating a rebound from a traditionally softer start to the year, with strength in Q2 prints for commercial franchises within its coverage, the analyst tells investors in a research note. Truist adds that it sees a robust catalyst calendar, supported by sector optimism and deal activity, as drivers for the recent momentum across the sector.
Truist analyst Gregory Renza lowered the firm's price target on Jazz Pharmaceuticals to $254 from $256 and keeps a Buy rating on the shares as part of a broader research note updating the firm's models and previewing Q2 earnings in Biotech.
The firm is anticipating a rebound from a traditionally softer start to the year, with strength in Q2 prints for commercial franchises within its coverage, the analyst tells investors in a research note.
Truist adds that it sees a robust catalyst calendar, supported by sector optimism and deal activity, as drivers for the recent momentum across the sector.